Drug profile · INN
amlexanox
APHTHASOL
amlexanox (APHTHASOL) is a phosphodiesterase 4 inhibitor. Route of administration: dental. Current US regulatory status: approved.
Drug details — amlexanox
- US status
- approved
- Class
- —
- Route
- DENTAL
- Patents
- 5
- Programs
- 20
- Data quality
- 0.84
Quick answer
amlexanox (APHTHASOL) is a phosphodiesterase 4 inhibitor. Route of administration: dental. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Phosphodiesterase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is amlexanox?
amlexanox (APHTHASOL) is a phosphodiesterase 4 inhibitor. Route of administration: dental. Current US regulatory status: approved.
What is the brand name for amlexanox?
APHTHASOL is a marketed brand name for amlexanox. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amlexanox?
amlexanox has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.